News and Trends 9 May 2023 Recursion boosts drug discovery with Cyclica and Valence acquisitions Recursion has signed agreements to acquire two companies in the AI-enabled drug discovery space: Cyclica, for $40 million, and Valence, for $47.5 million. Chris Gibson, co-founder and CEO of Salt Lake City headquartered Recursion, said: “Recursion has pioneered the massive, parallel generation of -omics data with machine learning in order to map and navigate biology […] May 9, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 May 2023 Researchers overcome stem cell delivery issues A recent study explains how researchers have devised a new method for delivering particles into stem cells, which are difficult to penetrate. The discovery will make it easier to direct and enhance the processes involved in regenerative medicine. Regenerative medicine takes advantage of the fact that our body’s stem cells can change into many other […] May 9, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 May 2023 Can tumor bacteria kill tumors? Japanese researchers say it may be possible to treat cancer using bacteria that naturally reside within tumors to trigger a powerful anticancer immune response.In recent years, interest in bacterial agents as anticancer therapeutics has grown, due to the ability of some bacteria to selectively grow inside hypoxic tumors, i.e., these cells do not receive rich […] May 9, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 May 2023 Fabry disease treatment gets EU marketing authorization Chiesi Global Rare Diseases and Protalix BioTherapeutics, Inc. have announced that the European Commission (EC) has granted marketing authorization to PRX-102 (pegunigalsidase alfa) in the European Union (EU) for the treatment of adult patients with Fabry disease. “People living with Fabry disease often perceive their disease as burdensome and still experience unmet medical needs,” said […] May 9, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Sponsored by Merck 9 May 2023 Separation and analysis of empty and filled capsids during viral vector production May 9, 2023 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 8 May 2023 How thalassemia gene therapy approval is making a difference A newly-approved gene therapy is transforming the lives of patients with beta thalassemia – an inherited blood disorder – by helping to stop or significantly reduce their reliance on blood transfusions, says an expert from a leading global health system, Cleveland Clinic, on International Thalassemia Day on May 8. A gene therapy known as betibeglogene […] May 8, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 5 May 2023Beyond Biotech podcast 44 This week’s podcast is sponsored by Lonza. May is Lupus Awareness Month, and to talk about lupus research with us this week on the podcast are Katherine Tran, senior global market development & marketing manager of the proteomics division at SCIEX, and Allan Stensballe, associate professor, Department of Health Science and Technology and associate professor, […] May 5, 2023 Share WhatsApp Twitter Linkedin Email
In Depth 5 May 2023 The biggest private biotech investments in April 2023 April 2023 saw the companies Orbital Therapeutics, Sangon Biotech, and Alentis Therapeutics bag the biggest biotech investments of the month. Around the world, oncology, drug discovery, food and biomaterials attracted the biggest funding rounds. With reports of venture capital investments in biotech and pharma hitting a more than three-year low last quarter, private biotech fundraising […] May 5, 2023 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 5 May 2023 Promising results from phase 3 prostate cancer study Astellas Pharma Inc. and Pfizer Inc. have announced trial results from a phase 3 study on prostate cancer. The results showed XTANDI (enzalutamide) plus leuprolide significantly reduced the risk of metastasis or death by 58% versus placebo plus leuprolide, as assessed by the primary endpoint of metastasis-free survival (MFS) in men with non-metastatic hormone-sensitive prostate […] May 5, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 May 2023 ‘Birth of a chromosome’ could boost cancer and infertility research Most chromosomes have been around for millions of years. However, researchers from the Stowers Institute for Medical Research have revealed the dynamics of a new, very young chromosome in fruit flies that is similar to chromosomes that arise in humans and is associated with treatment-resistant cancer and infertility. The researchers say the findings may lead […] May 5, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 May 2023 Exothera partners with Quantoom and launches DNA business unit Exothera has partnered with Quantoom Biosciences to gain access to Quantoom’s Nfinity technology, a continuous production platform for RNA. The partnership will enable Exothera to be the first CDMO in the world to offer this off-the-shelf process for the continuous production of RNA as a service. Continuous manufacturing of RNA can provide significant advantages in […] May 5, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 5 May 2023 Convergent Therapeutics to use $90M funding to treat cancer with radiopharmaceuticals Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on the development of next-generation radiopharmaceuticals for the treatment of cancer, today announced the completion of a $90 million Series A financing. The funding was led by OrbiMed and RA Capital Management with participation from Invus. The financing will support the development of a pipeline of novel […] May 5, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email